

The YODA Project Research Proposal Due Diligence Assessment

Part 1: General Information	
YODA Project (Protocol) ID:	2020-4444
Date:	26 October 2020
Product Name:	Methylphenidate HCl
Therapeutic Area:	Neuroscience
Product Class:	Stimulants/ADHD/Anorexiant
Condition(s) Studied:	Attention Deficit Hyperactivity Disorder
Protocol Number(s) and Title(s):	NCT00326391 02-159 NCT00326300 12-304 NCT00246220 42603ATT3002 NCT00307684 42603ATT3004 NCT00714688 42603ATT3013 NCT00937040 CONCERTA-ATT-3014 NCT00799409 CONCERTA-ATT-4069 NCT00799487 CONCERTA-ATT-4080 NCT01323192 JNS001-JPN-A01
Part 2: Data Availability	
Question:	Response:
Data Holder has authority to provide clinical trial data or development partner has agreed to share clinical trial data.	Yes
Comments: N/A	
Data Holder has sharable electronic clinical trial data or data can be converted to electronic format.	Yes
Comments: N/A	
De-identification and redaction of clinical trial data in accordance with current HIPAA and EU criteria allows protection of participant privacy and confidentiality.	Yes
Comments: N/A	
The product and relevant indication studied has either been approved by regulators in the US and EU, or terminated from development.	Yes
Comments: N/A	
Data Holder has completed the clinical trial and trial has been completed for a period of at least 18 months (or results published in peer-reviewed biomedical literature).	Yes
Comments: N/A	
Part 3: Data Availability Summary	
Based on the responses to the above Data Availability questions, the requested clinical trial data can be made available for data sharing.	Yes
Part 4: Proposal Review	
Question:	Response:
Summary-level CSR data is appropriate for the proposed analysis.	Yes
Participant-level data is appropriate for the proposed analysis.	Yes

The YODA Project
Research Proposal Due Diligence Assessment

A similar analysis is underway or completed/pending disclosure by Janssen.	No
Comments:	